Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii.

Bottova I, Sauder U, Olivieri V, Hehl AB, Sonda S.

PLoS One. 2010 Apr 8;5(4):e10062. doi: 10.1371/journal.pone.0010062.

2.

Host cell P-glycoprotein is essential for cholesterol uptake and replication of Toxoplasma gondii.

Bottova I, Hehl AB, Stefanić S, Fabriàs G, Casas J, Schraner E, Pieters J, Sonda S.

J Biol Chem. 2009 Jun 26;284(26):17438-48. doi: 10.1074/jbc.M809420200. Epub 2009 Apr 22.

4.

Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii.

Nagamune K, Beatty WL, Sibley LD.

Eukaryot Cell. 2007 Nov;6(11):2147-56. Epub 2007 Aug 31.

5.

Abscisic acid controls calcium-dependent egress and development in Toxoplasma gondii.

Nagamune K, Hicks LM, Fux B, Brossier F, Chini EN, Sibley LD.

Nature. 2008 Jan 10;451(7175):207-10. doi: 10.1038/nature06478.

6.

The calcium signaling toolkit of the Apicomplexan parasites Toxoplasma gondii and Plasmodium spp.

Lourido S, Moreno SN.

Cell Calcium. 2015 Mar;57(3):186-93. doi: 10.1016/j.ceca.2014.12.010. Epub 2014 Dec 31. Review.

8.
9.

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P.

Cancer Res. 2001 Jan 15;61(2):749-58.

10.
11.
12.

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y.

J Pharmacol Exp Ther. 2005 Jan;312(1):44-52. Epub 2004 Sep 24.

13.

A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.

Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.

Drug Metab Lett. 2012 Jun 1;6(2):134-44.

PMID:
23061481
14.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH.

J Clin Oncol. 2002 Jul 1;20(13):2943-50.

PMID:
12089223
15.

Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.

On NH, Chen F, Hinton M, Miller DW.

Pharm Res. 2011 Oct;28(10):2505-15. doi: 10.1007/s11095-011-0478-6. Epub 2011 May 20.

PMID:
21598079
16.

Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A.

Curr Eye Res. 2009 Jan;34(1):1-9. doi: 10.1080/02713680802518251.

17.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.

Clin Cancer Res. 2000 Nov;6(11):4416-21.

18.
19.

P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.

Kanaan M, Daali Y, Dayer P, Desmeules J.

Fundam Clin Pharmacol. 2009 Oct;23(5):543-8. doi: 10.1111/j.1472-8206.2009.00724.x. Epub 2009 Jul 28.

PMID:
19656202
20.

Supplemental Content

Support Center